WATERTOWN, Mass. --(BUSINESS WIRE)--Apr. 27, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

New data presented includes: - First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) - - LYR-210 (7500µg) decreased ethmoid

- LYR-210 is Lyra’s lead product candidate for chronic rhinosinusitis - WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 29, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions

- Positive Topline Results for LANTERN Phase 2 Study of LYR-210- - Robert Kern , MD, appointed Chief Medical Officer - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 9, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics

WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 2, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

Thought leader in the ENT treatment community brings insight from clinical practice to next stage of development for LYR-210 and pipeline WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 17, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and

WATERTOWN, Mass. --(BUSINESS WIRE)--Jan. 22, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)